Clinical trials: Follicular Lymphoma
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and…
- Conditions
- BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe
- Trial name
- NCT02210689
- Testing
- clindamycin phosphate vaginal cream 2%
- Where
- 18 sites in United States, Dominican Republic and 1 more
- Volunteers
- 604 people
- Sponsor
- Actavis Inc.
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive…
- Trial name
- NETTER-3 (NCT06784752)
- Testing
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Where
- 67 sites in United States, Canada and 10 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Mild and Moderate Alzheimer's Disease, Cognitively Healthy People
An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population
Difference in nutritional status between patients with mild and moderate Alzheimer's Disease (AD) and cognitively intact healthy people in an Asian population
- Trial name
- NCT02249468
- Where
- Singapore
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Danone Nutricia Research
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT05565417
- Testing
- IMT-009, Fruquintinib
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Immunitas Therapeutics
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell…
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
- Trial name
- NCT06093841
- Testing
- Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide
- Where
- 13 sites in China
- Volunteers
- 46 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Non-Hodgkin Lymphoma, DLBCL
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
The study will examine the safety profile of SGN-CD19B administered as a single agent. The main purpose of the study is to estimate the highest dose that does not cause unacceptable side effects of SGN-CD19B in patients with…
- Conditions
- Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma, Grade 3 Follicular Lymphoma
- Trial name
- NCT02702141
- Testing
- SGN-CD19B
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Seagen Inc.
Non-Hodgkin Lymphoma
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL…
- Trial name
- NCT00100737
- Testing
- interleukin-2, rituximab
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Chiron Corporation
Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized, dose-escalation study will evaluate the safety, efficacy, and pharmacokinetics of obinutuzumab in combination with idasanutlin and venetoclax in participants with R/R FL…
- Trial name
- NCT03135262
- Testing
- Idasanutlin, Obinutuzumab, Venetoclax
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Moderate or Severe Submental Fullness
Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
To evaluate the safety of deoxycholic acid subcutaneous injections in the submental area (below the chin).
- Trial name
- NCT01426373
- Testing
- Deoxycholic acid injection
- Where
- 18 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Moderate or Severe Nasolabial Folds
Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management
Rationale and background: Skin aging is a complex process that results in various changes in the skin, including wrinkles, sun spots, and sagging skin.
- Trial name
- NCT06509477
- Testing
- Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.), Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)
- Where
- Iran
- Volunteers
- 104 people
- Sponsor
- Espad Pharmed
Malnutrition; Mild, Iron-deficiency Anemia
The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers
It is well known than an important part of Nigerian children from the lower social economic class have nutrient deficiencies. Fortified products, such as growing up milks (GUM), may play an important role in reducing the risk and…
- Conditions
- Malnutrition; Mild, Iron-deficiency Anemia, Nutritional Stunting, Nutritional Wasting
- Trial name
- GaGA (NCT03411590)
- Testing
- Fortified milk Powder
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- FrieslandCampina WAMCO Nigeria PLC
Moderate or Severe Submental Fullness
Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study
Evaluation of the safety, tolerability and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- NCT01032889
- Testing
- Deoxycholic acid injection
- Where
- 10 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma.
- Conditions
- Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Trial name
- NCT05512390
- Testing
- ABBV-319
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 39 people
- Sponsor
- AbbVie
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
This will be a multicenter, national, non-interventional, prospective cohort study
- Conditions
- Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Follicular Lymphoma
- Trial name
- NCT05541341
- Testing
- tisagenlecleucel
- Where
- 7 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
B-cell Malignancy, Non-Hodgkin Lymphoma
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy…
- Conditions
- B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT05294731
- Testing
- Tacabrutideg
- Where
- 29 sites in China
- Volunteers
- 146 people
- Sponsor
- BeOne Medicines
Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non-Hodgkin lymphoma (NHL) relapsed…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse, Lymphoma, Follicular
- Trial name
- NCT03357627
- Testing
- TAK-659, Venetoclax
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 43 people
- Sponsor
- Calithera Biosciences, Inc
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04844086
- Testing
- RPM CD19-mbIL15-CAR-T cells
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- Eden BioCell Ltd.
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).
- Trial name
- NCT01693614
- Testing
- Buparlisib
- Where
- 20 sites in United States, Belgium and 6 more
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is…
- Conditions
- Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04323657
- Testing
- TC-110 T Cells, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- TCR2 Therapeutics
Lymphoma, Non-Hodgkin
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.
- Trial name
- NCT00045877
- Testing
- Recombinant Human Interleukin-2 and Rituximab
- Where
- 65 sites in United States
- Sponsor
- Chiron Corporation